SABS

Sab Biotherapeutics INC

+$129.8M

Net Activity

Institutions Holding

79

Popularity Rank

#4983

Avg Weight

0.19%

Total Value

$265.8M

Ownership Trend

79 institutions currently hold SABS, with 59 net buyers and 11 net sellers this quarter.

Institutional Moves

Institutional Moves (Q1 2026)

Significantly Increased

Based on recent trading activity

Net Selling Institutions

11

Net Buying Institutions

59

Key Holders

View all 79 holding institutions

Quarterly Activity

Recent Activity

+$158.7M

Total Buy Value

$1.7M

Total Sell Value

New buy34
Trim6
Add25
Sold out5

59

Net Buyers

11

Net Sellers

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

1

Filings (14d)

Data as of 2026-07-07

View all Form 8-K filings

FAQ

Who are the top institutional investors holding SAB BIOTHERAPEUTICS INC (SABS)?
Major stakeholders currently include Vivo Capital, LLC ($43.7M), Caligan Partners LP ($30.5M), Perceptive Advisors LLC ($24.6M). Based on the latest 13F filings, there are a total of 79 tracked investment funds and institutions maintaining positions in SABS.
What is the overall institutional sentiment toward SABS recently?
Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $129.8M, driven by 59 managers accumulating shares while 11 reduced their exposure.
Which institutions have been selling or reducing their SABS positions?
In the latest period, 6 funds trimmed their holdings, and 5 managers completely exited their positions. The aggregate reported sell value was $1.7M.
Are there any notable investors adding SABS to their portfolios?
Yes, buying activity remains notable. 34 institutions opened new positions in {ticker}, and 25 existing holders added to their shares. The total reported buy value for the quarter amounted to $158.7M.

Related Stocks